Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
266.57
+10.01 (3.90%)
Dec 20, 2024, 4:00 PM EST - Market closed
Insulet Revenue
Insulet had revenue of $543.90M in the quarter ending September 30, 2024, with 25.70% growth. This brings the company's revenue in the last twelve months to $1.98B, up 27.42% year-over-year. In the year 2023, Insulet had annual revenue of $1.70B with 30.02% growth.
Revenue (ttm)
$1.98B
Revenue Growth
+27.42%
P/S Ratio
9.41
Revenue / Employee
$661,300
Employees
3,000
Market Cap
18.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Molina Healthcare | 37.54B |
| Labcorp Holdings | 12.71B |
| Quest Diagnostics | 9.54B |
| ICON Public Limited Company | 8.31B |
| STERIS | 5.33B |
| Hologic | 4.03B |
| The Cooper Companies | 3.90B |
| BeiGene | 3.35B |
PODD News
- 16 days ago - Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case - Reuters
- 17 days ago - Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court - Business Wire
- 4 weeks ago - Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines - Seeking Alpha
- 4 weeks ago - Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S. - Business Wire
- 5 weeks ago - Insulet to Present at Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Buy, Sell, Or Hold Insulet (PODD) Stock? - Forbes
- 5 weeks ago - Top 4 Health Care Stocks That May Plunge This Quarter - Benzinga
- 6 weeks ago - Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript - Seeking Alpha